🚨 More IP momentum for #POLB 🇮🇱 @PoolbegPharma has received a Notice of Allowance for its POLB 001 cancer immunotherapy-induced CRS patent application in Israel. This follows patent progress in Europe, Australia and Canada, further strengthening the global IP estate around its lead asset. With clinical development advancing and a growing patent portfolio, POLB 001 continues to build its commercial appeal for potential partners. 👀 Another important milestone for #PoolbegPharma. https://t.co/yQ55nmup9T #Biotech #CancerImmunotherapy #AIM #Healthcare #Investing
David Burton ⭐️⭐️Share
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.